Glenmark Pharmaceuticals announced that its wholly owned subsidiary, Ichnos Glenmark Innovation (IGI), has received an upfront payment of $700 million from AbbVie (NYSE: ABBV).
The payment follows through on the terms of the exclusive global licensing agreement signed between the two companies. Under this deal, AbbVie has secured worldwide rights to IGI’s lead investigational asset, ISB 2001, across major markets including North America, Europe, Japan, and Greater China.
This collaboration, first disclosed on July 10, 2025, marks one of Glenmark’s most significant licensing partnerships to date. The upfront milestone strengthens Glenmark’s financial position while also validating IGI’s research and development pipeline.
The ISB 2001 program is being closely watched by the global pharmaceutical industry for its potential in addressing unmet medical needs. With AbbVie’s expertise in commercialization and development, the agreement is expected to accelerate the drug’s journey from clinical stages to global market availability.
